Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Programming and Data Management Director
Automation and Semantic Interoperability in Clinical Trials
Yama F Mujadidi is the Programming and Data Management Director at the Oxford Vaccine Group. In this role, he provides strategic leadership across the Group’s global portfolio of clinical research, with responsibility for data governance, IT infrastructure, programming, and data management systems.
With more than a decade of experience in clinical trials data management and software engineering, he has led the development and validation of electronic data capture systems (MHRA/GxP/FDA compliant), large-scale database infrastructures, and large language models. His expertise spans information governance, clinical trial regulations, and project management, underpinned by a proven ability to lead multidisciplinary technical teams.
Since joining the Oxford Vaccine Group in 2013, Yama has contributed to major international vaccine trials, trained and mentored research teams in the UK and globally, and co-authored numerous publications in high-impact journals. He has also taken a leading role in advancing novel approaches to clinical trial database design and semantic interoperability.
His achievements have been recognised through several awards, including the Fazlur Rahman Khan Award for Excellence in Engineering and Science (2013), the Association for Clinical Data Management’s Individual Excellence Award (2024), and recognition as Best Muslim in STEM by British Muslim (2024).
Beyond Oxford, Yama is an entrepreneur and founder of organisations advancing educational and technological innovation for global health. He is currently pursuing a DPhil at the University of Oxford on automation and semantic interoperability in clinical trials. Alongside his academic and professional commitments, he serves as a delegate with UN Women UK, advocating for the rights of women and children.
Recent publications
8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial.
Journal article
Pant D. et al, (2027), Lancet Glob Health
Establishing a human co-infection challenge study of Streptococcus pneumoniae (Spn) and live attenuated influenza vaccine (LAIV) in older healthy adults: Exploring Co-infection with Live Attenuated Influenza Vaccine and PneumococcuS in healthy oldEr adults (ECLIPSE), a UK-based single-centre, single-blind randomised controlled trial.
Journal article
Jackson RI. et al, (2026), BMJ Open, 16
Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20) compared with PCV13 given in homologous schedules at 3 months and 12 months ('1+1' schedule) and 2 months, 4 months and 12 months ('2+1' schedule) in infants: protocol.
Journal article
Aslam R. et al, (2026), BMJ Open, 16
Persistence of immune responses 5 years after vaccination with a single dose of typhoid conjugate vaccine (TCV) in Nepalese children.
Journal article
Pant D. et al, (2026), Vaccine, 92
Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: An observational study.
Journal article
Zhang Y. et al, (2026), J Infect, 93
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
Journal article
Ebrahimi N. et al, (2026), Vaccine, 88
COVID-19 vaccine effectiveness and SARS-CoV-2 variants in Nepal: Test-negative case-control study and genetic sequencing (COVVAR Nepal)
Journal article
Pokhrel B. et al, (2026), Vaccine X, 31
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
Journal article
Bijukchhe SM. et al, (2026), Lancet Infect Dis, 26, 726 - 738
Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.
Journal article
Kelleher K. et al, (2026), BMJ Open, 16
The association between vaccine coverage and herd protection: exploratory analyses of a cluster-randomised trial of Vi conjugate vaccine.
Journal article
Zhang Y. et al, (2026), EClinicalMedicine, 94
Preliminary safety data from a randomised trial of early versus standard timing of administration of measles-rubella vaccine in Ugandan infants.
Journal article
Businge G. et al, (2026), Discov Med (Singap), 3
Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Journal article
Kelly E. et al, (2026), J Infect, 92
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Journal article
Janani L. et al, (2025), J Infect, 91
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.
Journal article
Amini A. et al, (2025), Sci Immunol, 10
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal article
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9
Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model.
Journal article
Ashton PM. et al, (2025), Microbiome, 13
Precision Data Management: Using REDCap and Large Language Models to Optimise Clinical Trial Efficiency
Preprint
Mujadidi YF. et al, (2025)
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.
Journal article
Chanda C. et al, (2025), Lancet Microbe, 6
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Journal article
Feng S. et al, (2025), J Infect, 90
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Journal article
Conlin K. et al, (2025), Vaccine, 45
PROTECTION CONFERRED BY A SINGLE DOSE OF TYPHOID CONJUGATE VACCINE AMONG BANGLADESHI CHILDREN AFTER FIVE YEARS OF VACCINATION: ANALYSIS OF A CLUSTER RANDOMIZED CONTROLLED TRIAL
Conference paper
Khanam F. et al, (2025), AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 112
Five-Year Vaccine Protection Following a Single Dose of Vi-Tetanus Toxoid Conjugate Vaccine in Bangladeshi Children: A Cluster Randomised Trial
Journal article
Qadri F. et al, (2024)
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Journal article
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.
Journal article
Dyson ZA. et al, (2024), Lancet Microbe, 5
Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.
Journal article
Khaki JJ. et al, (2024), Sci Rep, 14
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Journal article
Jackson S. et al, (2024), Lancet Microbe, 5, 655 - 668